Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
CARTIER, Lysian
PRESTO, NCT04115007: Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients	Recruiting	3	550	Europe, RoW	Stereotactic Body Radiotherapy (SBRT) + Standard of care, Standard of care	UNICANCER	Oligometastatic Hormone Sensitive Prostate Cancer	06/26	02/31
DARIUS, NCT05346848 / 2022-002431-53: Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer	Recruiting	2	62	Europe	Association of darolutamide and EBRT, Association of ADT and EBRT	Institut Bergonié, Bayer	Prostate Cancer	08/25	02/30
OLIGOPELVIS2, NCT03630666: Comparison of Intermittent Androgen Deprivation Therapy With or Without Irradiation Recovery in Prostate Cancer Patients	Active, not recruiting	N/A	256	Europe	IADT, LH-RH (Luteinizing Hormone Releasing Hormone) agonist, IADT + radiotherapy, IG-IMRT	Institut Cancerologie de l'Ouest, Direction Générale de l'Offre de Soins, Astellas Pharma Inc	Prostate Cancer, Oligometastasis	06/26	06/26